NIH Offers New Cell Therapy to Fight HPV Warts
Published Date: 7/16/2026
Notice
Summary
The National Cancer Institute has created a new way to make special immune cells called PILs that can fight chronic HPV infections causing painful growths in the throat and genital areas. This new cell therapy could reduce the need for repeated surgeries, improving patients’ lives and cutting healthcare costs. Researchers are now looking for partners to help develop and license this promising treatment soon.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Potential New Therapy for Chronic HPV 6/11
Researchers at the National Cancer Institute developed papilloma-infiltrating lymphocytes (PILs) to treat chronic human papillomavirus (HPV) type 6 or 11 infections that cause recurrent respiratory papillomatosis (RRP) and anogenital condyloma. This approach could reduce the need for repeated surgical debulking or laser ablation, improve quality of life, and cut ongoing healthcare costs for patients with chronic HPV 6/11 infections.
License and Co-Development Opportunity for Biotech
The National Cancer Institute is seeking industry partners to license and co-develop PIL cell therapy for HPV 6/11 conditions; the technology is at pre-clinical (in vivo validation) stage and carries NIH Reference Number E-143-2024-0. A PCT patent application was filed on October 20, 2025 (PCT/US2025/051640), and interested biotech firms focused on T cell therapies are invited to pursue licensing or collaboration.
RRP Drug Development May Qualify for Incentives
The notice states drug development for recurrent respiratory papillomatosis (RRP) may qualify for regulatory incentives due to the rarity of the disease. Sponsors developing PIL-based therapies for RRP could be eligible for such incentives during clinical development and regulatory review.
Method Could Enable Broader Non‑Cancer Treatments
The NCI reports the PIL manufacturing method can isolate and expand antigen-specific lymphocytes from non-cancerous papilloma tissue, potentially enabling adoptive cell therapies for a broader range of non-malignant diseases and supporting generation of T cell receptor (TCR) libraries for research and therapeutic use.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17687, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in October 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, ensuring fair and confidential decisions. Scientists applying for grants in genetics, molecular sciences, oral health, and cancer research are the ones affected, with no direct cost changes announced.
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
Previous / Next Documents
Previous: 2026-14346, Government Owned Invention Available for License: Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy
The National Cancer Institute has invented a cool new way to grow special immune cells called TCR-T cells that can better fight cancer. This method helps companies make more powerful, targeted cell therapies by boosting the right cells and cutting out the extras. If you’re in biotech or cancer treatment, this is your chance to license a game-changing tool that could speed up cancer cures and bring new treatments to patients faster.
Next: 2026-14349, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Grazing Management: Range Improvement Agreements and Permits Materials
The Bureau of Land Management wants to keep collecting info about grazing permits and improvements on public lands, making sure the paperwork stays clear and easy. Ranchers and land users are affected, but no big changes or costs are expected. You’ve got until August 17, 2026, to share your thoughts and help keep things smooth and simple!